Toujeo Set For Tresiba Face-Off After Japan Approval
This article was originally published in PharmAsia News
Executive Summary
Sanofi's Toujeo is set to compete with Novo's Tresiba in Japan following its approval in this market, while Gilead has also secured a regulatory clearance for its hepatitis C combination Harvoni and Kyowa Kirin for a recombinant antithrombotic preparation.